Imunon, INC Form 4 insider transactions

Frederick J. Fritz, a Director of Imunon, Inc., received 6,934 shares of common stock on July 31, 2026.

Susan Eylward, General Counsel and Corp Sec of Imunon, Inc., sold 2,541 shares of common stock on July 31, 2026 for $1.57 per share.

Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc., received 3,649 shares of common stock on July 31, 2026.

Stacy Lindborg, President and CEO and a Director of Imunon, Inc., received 5,010 shares of common stock on July 31, 2026.

Michael H Tardugno, Executive Chairman of Board and a Director of Imunon, Inc., received 4,603 shares of common stock on July 17, 2026.

Susan Eylward, General Counsel and Corp Sec of Imunon, Inc., sold 2,150 shares of common stock on July 17, 2026 for $1.78 per share.

Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc., received 3,082 shares of common stock on July 17, 2026.

Stacy Lindborg, President and CEO and a Director of Imunon, Inc., received 4,907 shares of common stock on July 17, 2026.

Imunon, Inc. reports that Executive Chairman Michael H. Tardugno acquired 4,410 shares of common stock on July 2, 2026, valued at $1.91 per share, as compensation for services.

Susan Eylward, General Counsel and Corp Sec of Imunon, Inc., reported transactions involving common stock, including stock granted in lieu of salary.

Imunon, Inc. reports that Chief Medical Officer Douglas Vincent Faller acquired 1,308 shares of common stock on July 2, 2026, valued at $1.91 per share, as part of a stock grant in lieu of cash for a portion of his base salary.

Stacy Lindborg, President and CEO of Imunon, Inc., acquired 2,534 shares of common stock on July 2, 2026, valued at $1.91 per share, as part of her compensation.

Imunon, Inc. reports a stock grant to Chief Medical Officer Douglas Faller, issued in lieu of a cash bonus.

Imunon, Inc. reports a stock grant to General Counsel Susan Eylward and subsequent sale of shares.

Michael H. Tardugno, Executive Chairman of Imunon, Inc., acquired 42,519 shares of common stock on June 25, 2026, in lieu of a cash bonus.

Stacy Lindborg, President and CEO of Imunon, Inc., acquired 67,150 shares of common stock on June 25, 2026, valued at $1.72 per share, as part of her 2025 annual bonus.

Executive Chairman Michael H. Tardugno acquired 4,089 shares of Imunon, Inc. common stock as compensation in lieu of cash salary.

Stacy Lindborg, President and CEO of Imunon, Inc., acquired 1,593 shares of common stock on June 5, 2026, valued at $2.06 per share, as part of a stock grant in lieu of cash for salary.

Michael H. Tardugno, Executive Chairman of Imunon, Inc., reported a transaction involving the acquisition of 3,484 shares of common stock on May 22, 2026, at a price of $2.2 per share.

Christine A. Pellizzari, a Director at Imunon, Inc., acquired 5,557 shares of common stock on May 22, 2026, valued at $2.20 per share.

Imunon, Inc. Director James E. Dentzer reports acquisition of 11,148 shares of common stock.

Donald P. Braun, a Director at Imunon, Inc., acquired 5,011 shares of common stock on May 22, 2026, as compensation for board fees.

Imunon, Inc. reports a Form 4 filing detailing the acquisition of common stock by Director Frederick J. Fritz as compensation for board services.

Stacy Lindborg, President and CEO of Imunon, Inc., acquired 1,491 shares of common stock on May 22, 2026, as part of her compensation.

Imunon, Inc. President and CEO Stacy Lindborg was granted 56,187 stock options with an exercise price of $3.95, vesting over two years.

Imunon, Inc.'s CFO, Kimberly Bragg, was granted 9,050 stock options with an exercise price of $3.95, vesting over two years.

Imunon's Chief Scientific Officer, Khursheed Anwer, was granted 15,736 stock options with an exercise price of $3.95, aligning executive incentives with shareholder value.

Imunon, Inc. Director Frederick J. Fritz acquired 5,892 stock options with an exercise price of $3.95, vesting over two years.

Imunon's Chief Medical Officer, Douglas Vincent Faller, was granted 12,667 stock options with an exercise price of $3.95.

Imunon, Inc.'s General Counsel and Corporate Secretary, Susan Eylward, was granted 8,251 stock options with an exercise price of $3.95.